Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146238081> ?p ?o ?g. }
- W2146238081 endingPage "337" @default.
- W2146238081 startingPage "337" @default.
- W2146238081 abstract "Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety Martin-Walter Welker, Joerg TrojanMedizinische Klinik 1, Universitätsklinikum Frankfurt, GermanyAbstract: Hepatocellular carcinoma (HCC) is a severe complication of advanced liver disease with a worldwide incidence of more than 600,000 patients per year. Liver function, clinical performance status, and tumor size are considered in the Barcelona Clinic Liver Cancer (BCLC) system. While curative treatment options are available for early stages, most patients present with intermediate- or advanced-stage HCC, burdened with a poor prognosis, substantially influenced by the degree of liver-function impairment. Hypervascularization is a major characteristic of HCC, and antiangiogenic treatments are the basis of treatment in noncurative stages, including interventional and pharmacological treatments. Currently, the tyrosine-kinase inhibitor sorafenib is still the only approved drug for HCC. Further improvements in survival in patients with intermediate- and advanced-stage HCC may be anticipated by both multimodal approaches, such as combination of interventional and systemic treatments, and new systemic treatment options. Until now, the Phase III development of other tyrosine-kinase inhibitors in patients with advanced HCC has failed due to minor efficacy and/or increased toxicity compared to sorafenib. However, promising Phase II data have been reported with MET inhibitors in this hard-to-treat population. This review gives a critical overview of antiangiogenic drugs and strategies in intermediate- and advanced-stage HCC, with a special focus on safety.Keywords: HCC, sorafenib, antiangiogenesis, TACE, MET" @default.
- W2146238081 created "2016-06-24" @default.
- W2146238081 creator A5020048563 @default.
- W2146238081 creator A5053037783 @default.
- W2146238081 date "2013-10-01" @default.
- W2146238081 modified "2023-10-16" @default.
- W2146238081 title "Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety" @default.
- W2146238081 cites W120079450 @default.
- W2146238081 cites W1521700858 @default.
- W2146238081 cites W1538245709 @default.
- W2146238081 cites W1546500689 @default.
- W2146238081 cites W1558726098 @default.
- W2146238081 cites W1586421535 @default.
- W2146238081 cites W1601002325 @default.
- W2146238081 cites W1604740730 @default.
- W2146238081 cites W1928548769 @default.
- W2146238081 cites W1964100554 @default.
- W2146238081 cites W1965309017 @default.
- W2146238081 cites W1965929829 @default.
- W2146238081 cites W1969947714 @default.
- W2146238081 cites W1970986474 @default.
- W2146238081 cites W1971837077 @default.
- W2146238081 cites W1975293227 @default.
- W2146238081 cites W1984322505 @default.
- W2146238081 cites W1984632950 @default.
- W2146238081 cites W1992253423 @default.
- W2146238081 cites W1992995480 @default.
- W2146238081 cites W1994193851 @default.
- W2146238081 cites W1994668492 @default.
- W2146238081 cites W1995811009 @default.
- W2146238081 cites W1996229105 @default.
- W2146238081 cites W1996958662 @default.
- W2146238081 cites W1998832059 @default.
- W2146238081 cites W2001406613 @default.
- W2146238081 cites W2016094100 @default.
- W2146238081 cites W2016278725 @default.
- W2146238081 cites W2016364458 @default.
- W2146238081 cites W2019367792 @default.
- W2146238081 cites W2019961689 @default.
- W2146238081 cites W2020299781 @default.
- W2146238081 cites W2020509813 @default.
- W2146238081 cites W2020531037 @default.
- W2146238081 cites W2022119530 @default.
- W2146238081 cites W2022169488 @default.
- W2146238081 cites W2022454793 @default.
- W2146238081 cites W2023250239 @default.
- W2146238081 cites W2023530235 @default.
- W2146238081 cites W2026184172 @default.
- W2146238081 cites W2030906858 @default.
- W2146238081 cites W2033802014 @default.
- W2146238081 cites W2037819581 @default.
- W2146238081 cites W2038625523 @default.
- W2146238081 cites W2040552696 @default.
- W2146238081 cites W2040851157 @default.
- W2146238081 cites W2042571415 @default.
- W2146238081 cites W2055779035 @default.
- W2146238081 cites W2056116577 @default.
- W2146238081 cites W2056379954 @default.
- W2146238081 cites W2056775161 @default.
- W2146238081 cites W2057776202 @default.
- W2146238081 cites W2057888035 @default.
- W2146238081 cites W2059377623 @default.
- W2146238081 cites W2061345986 @default.
- W2146238081 cites W2063938081 @default.
- W2146238081 cites W2073858660 @default.
- W2146238081 cites W2076465532 @default.
- W2146238081 cites W2078031849 @default.
- W2146238081 cites W2080663543 @default.
- W2146238081 cites W2081557581 @default.
- W2146238081 cites W2085106601 @default.
- W2146238081 cites W2085547877 @default.
- W2146238081 cites W2087658241 @default.
- W2146238081 cites W2089449278 @default.
- W2146238081 cites W2094337993 @default.
- W2146238081 cites W2096844786 @default.
- W2146238081 cites W2100106896 @default.
- W2146238081 cites W2100297634 @default.
- W2146238081 cites W2101270301 @default.
- W2146238081 cites W2105831274 @default.
- W2146238081 cites W2106036268 @default.
- W2146238081 cites W2109746877 @default.
- W2146238081 cites W2111464526 @default.
- W2146238081 cites W2113222623 @default.
- W2146238081 cites W2115497785 @default.
- W2146238081 cites W2124136612 @default.
- W2146238081 cites W2124426490 @default.
- W2146238081 cites W2125763116 @default.
- W2146238081 cites W2127718637 @default.
- W2146238081 cites W2130210996 @default.
- W2146238081 cites W2130325374 @default.
- W2146238081 cites W2130575786 @default.
- W2146238081 cites W2132215313 @default.
- W2146238081 cites W2132874779 @default.
- W2146238081 cites W2136977965 @default.
- W2146238081 cites W2137052325 @default.
- W2146238081 cites W2140587309 @default.
- W2146238081 cites W2145271725 @default.
- W2146238081 cites W2145456312 @default.